Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group.
about
Care models in the management of haemophilia: a systematic reviewItalian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis.Haemophilia utilization group study - Part Va (HUGS Va): design, methods and baseline data.Linking medicine and economics: health economics and quality of life in haemophilia care.The impact of chronic disease on the family.Home management of haemophilia.Outcome measures in haemophilia: more than just factor levels.Quality of life assessment in haemophilia.Osteoporosis in haemophilic patient, rehabilitative aspects.New treatments in hemophilia: insights for the clinician.Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders.Current options and new developments in the treatment of haemophilia.On-demand treatment in persons with severe haemophilia.Assessing health-related quality-of-life in individuals with haemophilia.Prophylaxis use among males with haemophilia B in the United States.Real-world resource use and costs of haemophilia A-related bleeding.Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries.Establishing a harmonized haemophilia registry for countries with developing health care systems.Haemophilia care in Europe: the ESCHQoL study.Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome.Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study.The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada.Prophylaxis for severe haemophilia: clinical and economical issues.Financial aspects of haemophilia care in Puerto Rico and other Latin American countries.Pathogenesis of haemophilic synovitis: clinical aspects.Meta-analysis on the effectiveness of B-domain deleted factor VIII for prophylaxis.EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France.Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors.Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX.Increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII--a robust meta-analytic finding.Guidelines for the management of hemophilia.Cost of severe haemophilia in Toronto.
P2860
Q30249304-A77A65FC-073B-47EF-A8FC-CD232893DCC1Q33324733-C5B7DD7C-A4FA-4FC9-993E-971DCA22D225Q33937275-F24D9FE9-E453-4629-A66C-B9A9C4961665Q34636921-530AE092-81BE-4432-A0BC-8DBF26EAA25AQ34637156-00F3A0FD-046D-4848-8610-DBE90B45C05CQ35666730-9CA33D2C-868E-4891-8D27-525D37EEA50DQ35676998-F37E8146-9DE1-41B2-8CED-3209F281B8B1Q35677000-959E2217-EC4E-48D5-99CB-7159F1D17005Q36333470-EDEEA847-769C-48B5-A761-642F829118CAQ36612681-2FE3B222-4C21-4212-BB84-0096DA9FA867Q37778291-203659ED-E9A4-43B7-91C5-858A2316A172Q37841547-9660CCC8-3901-4AE3-B895-58D893F19931Q38222575-4143E8CF-669B-4503-AB87-0559A99CFEF1Q38498570-5060A065-45AE-4DB4-9553-2EDE1F995387Q38638489-F89F0608-C4DA-4C45-BF59-184F691071D1Q38675749-1C56ED6B-F4A2-4115-A12B-2506A148FB6BQ38739036-243FB81A-C468-4D47-A50F-E7D365DF2CD1Q39434363-264D3764-C420-4C81-A1E0-6F7404E8D820Q45077924-F1EDE7E8-F107-423D-9BDD-D529FB97C921Q45855990-F88C2E44-15ED-4447-ACAB-83EF3EECE65EQ45855994-62F63B3D-9498-4633-9A27-58C53224B333Q45858388-AA9896B3-6F98-4D0C-B27C-85C541FA9C21Q45861966-96BFBD61-E3F1-4752-80FE-20EC534CE369Q45863205-A51DA7EE-75CF-4628-AFBE-970B6A5E34D5Q45863754-35A99207-1CFF-4275-9FC9-98BFD41412AAQ45870769-4E06CCC4-13A0-4355-BEA0-F800868B41F2Q45872099-E0D459E7-FB1E-4BF7-BC18-AD2C56E1224DQ45872775-5CA2BA6D-1168-474E-8950-F8F57762C483Q45875250-E04F7E32-478B-4522-96C4-46622F4497C6Q45877571-F6226E73-5B09-4DB8-A887-71E35D1F27C9Q45877725-3F748046-6487-4FC8-9480-43A4A07C7BBEQ45880345-214B2D02-F6C8-4E9E-9F0B-633539C165E6Q45883312-19ACEF5A-4792-49A4-8AB6-B2E300575CFC
P2860
Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Resource utilisation in haemop ...... ean Socioeconomic Study Group.
@en
Resource utilisation in haemop ...... ean Socioeconomic Study Group.
@nl
type
label
Resource utilisation in haemop ...... ean Socioeconomic Study Group.
@en
Resource utilisation in haemop ...... ean Socioeconomic Study Group.
@nl
prefLabel
Resource utilisation in haemop ...... ean Socioeconomic Study Group.
@en
Resource utilisation in haemop ...... ean Socioeconomic Study Group.
@nl
P2093
P1433
P1476
Resource utilisation in haemop ...... ean Socioeconomic Study Group.
@en
P2093
P304
P356
10.1046/J.1365-2516.1998.440498.X
P577
1998-07-01T00:00:00Z